Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Cephalon To Co-Market Vivitrex With Alkermes Through $500 Mil. Deal

This article was originally published in The Pink Sheet Daily

Executive Summary

The alcohol dependence therapy, which could be approved in September, will initially target patients already on pharmaceutical treatment. Cephalon will pay Alkermes $160 mil. upfront and could pay an additional $110 mil. if the agent is approved, on top of other milestone payments and profit sharing arrangements.

You may also be interested in...

Alcohol Dependence Treatment Vivitrol “Approvable”

Alkermes/Cephalon expect to launch the renamed once-monthly naltrexone injection in the second quarter.

NDAs Should Include More Cross-Study Analysis, FDA Says In Draft Guidance

FDA is clarifying that it expects sponsors to provide analysis of efficacy data rather than simply a summary of clinical data as part of the integrated summary of effectiveness in new drug applications


Latest News
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts